Background
==========

Congenital adrenal hyperplasia (CAH) refers to a family of autosomal recessive inherited disorders characterized by defects in the enzymatic steps required for cortisol synthesis. Adrenocorticotropic hormone (ACTH) levels increase due to a negative feedback system resulting in adrenocortical hyperplasia.

In the vast majority (90--95%), CAH is due to 21-hydroxylase deficiency (21-OHD). Classical CAH is classified into two types: the salt wasting and the simple virilizing. Salt wasting 21-OHD accounts for approximately 75% of the patients presenting with both signs of androgen excess and symptoms of mineralocorticoid deficiency, the latter being absent in the remaining 25% presenting the simple virilizing type. Non-classical CAH presents with milder symptoms and usually becomes evident in late childhood or early adulthood [@bib1].

11β-hydroxylase (CYP11B1) deficiency (11OHD; OMIM +202010) is the second most common cause of CAH accounting for approximately 5--8% of cases with an incidence of 1:100 000--1:200 000 live births in non-consanguineous populations [@bib1]. This cytochrome-P450 mitochondrial enzyme enhances conversion of 11-deoxycortisol to cortisol and 11-deoxycorticosterone (DOC) to corticosterone. Enzyme blockade stimulates ACTH secretion via a negative feedback mechanism resulting in accumulation of precursors that serve as substrates for androgen pathways and thus androgen excess and DOC overproduction as well. DOC, although a less potent mineralocorticoid, causes sodium retention, volume expansion and renin suppression. Subsequently, typical CYP11B1 deficiency presents with virilization, which in contrast to 21-OHD, is accompanied with a form of low-renin hypertension [@bib1]. However, among the approximately 90 different identified mutations, clinical and biochemical spectrum is variable [@bib2] [@bib3].

Despite the fact that CYP11B1 deficiency is the second more common form of CAH, no patient with this disorder has been reported from Greece. Herein, we describe a Greek patient with CAH due to compound heterozygosity for two novel mutations in *CYP11B1.*

Case presentation
=================

A 13-month-old girl of Greek origin presented to the pediatric endocrinology clinic of Attikon University Hospital in Athens because of pubic hair development since the age of 3 months. She is the second child of healthy non-consanguineous parents, born full-term with a birth weight of 3220 g (50th centile) and length of 50 cm (50th centile). Family history was unremarkable. At presentation growth parameters were normal: body length was 81 cm (90th centile) and weight was 11 400 g (90th centile). Physical examination revealed signs of mild androgen excess; pubic hair was Tanner stage 2, while axilla was rated stage 1. There was slight labial fusion and anogenital ratio was 0.67. Clitoris was normal and breast gland unpalpable. Psychomotor development was normal for age as was the rest of the physical examination. Bone age was advanced (27 months old). Blood pressure was normal for age (96/61 mmHg).

Investigation
=============

Routine laboratory evaluation, including blood urea nitrogen and serum electrolytes, was within normal range. Androgen levels were found to be elevated: 17-hydroxyprogesterone, 7.37 ng/ml (normal 0.2--0.5 ng/ml); testosterone, 39 ng/dl (normal 2--10 ng/dl); Δ4-androstenedione (Δ4A), 3.6 ng/ml (normal 0.1--0.2 ng/ml); DHEAS, 126 μg/dl (normal 0.5--19.4) and 11-deoxycortisol, 38.1 ng/ml (normal \<6 ng/ml). Plasma ACTH was also elevated at 83.8 pg/ml (normal 5--60 pg/ml), whereas serum cortisol was normal at 15.5 μg/dl. Serum aldosterone levels were normal at 42 ng/dl, while plasma renin activity was surprisingly elevated at 23 ng/ml per h ([Table 1](#tbl1){ref-type="table"}). The highly elevated 11-deoxycortisol levels combined with the elevated 17-hydroxyprogesterone and ACTH levels, accompanied with clinical signs of androgen excess, set the suspicion of CAH due to 11β-hydroxylase deficiency (11β-OHD). The girl then underwent a standard ACTH stimulation test (Tetracosactide, Defiante Farmaceutica, S.A., Funchal, Portugal) and results were compatible with the provisional diagnosis ([Table 2](#tbl2){ref-type="table"}).

###### 

Hormone evaluation at diagnosis

  **Laboratory findings**          **Patient values**   **Normal values**
  -------------------------------- -------------------- -------------------
  DHEAS (μg/dl)                    126                  0.5--19.4
  Δ4-androstenedione (ng/ml)       3.6                  0.1--0.2
  17-hydroxyprogesterone (ng/ml)   7.37                 0.2--0.5
  11-deoxycortisol (ng/ml)         38.1                 \<6
  Cortisol (μg/dl)                 15.5                 4--24
  Testosterone (ng/dl)             39                   2--10
  ACTH (pg/ml)                     83.8                 5--60
  PRA (ng/ml per h)                23                   \<10
  Aldosterone (ng/dl)              42                   5--90

###### 

Hormone evaluation before and after synacthen stimulation

  **Hormones evaluatated**         **Time** (min)   
  -------------------------------- ---------------- ------
  DHEAS (μg/dl)                    190              195
  11-deoxycortisol (ng/ml)         38.1             163
  17-hydroxyprogesterone (ng/ml)   2.2              7.04
  Δ4-androstenedione (ng/ml)       2.2              3.5
  Cortisol (μg/dl)                 10.4             15.9
  Testosterone (ng/dl)             25               36

Blood samples of the proband and her parents were shipped to the Service Endocrinologie Moleculaire et Maladies Rares in Bron Cedex, France, for molecular analysis of the CYP11B1 gene after receiving informed consent from the parents. Genomic DNA was isolated from whole blood using the PureLink Genomic DNA extraction kit (Invitrogen, Life Technologies). Coding and intron-exon junction regions of *CYP11B1*were amplified by PCR reaction using primers whose sequences differed from *CYP11B2*, as previously described [@bib4]. One μl of each PCR product was amplified with 0.5 U of Platinum Taq polymerase (Invitrogen, Life Technologies) and 0.6 μM of each primer in a final reaction volume of 25 μl using nested PCR [@bib5]. The smaller PCR products were screened for mutations in an ABI genetic analyzer (310 Applied Biosystems). Sequencing of the coding and respective adjacent intronic regions of the *CYP11B1* (NG_007954.1) gene revealed two novel genetic alterations: c.1157C\>A (p.Ala386Glu) in exon 7 and c.1412T\>G (p.Leu471Arg) in exon 9 ([Fig. 1](#fig1){ref-type="fig"}) Targeted genotyping performed in proband\'s parents revealed that p.Ala386Glu was inherited from the father (carrier) while p.Leu471Arg was inherited from the mother. Neither of the mutations has been reported so far. Neither change was detected after the screening of 100 alleles of individuals selected as controls. Both mutations are predicted to be 'possibly damaging' (scores 0.457 and 0.537 for exons 7 and 9 respectively) according to PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) Software.

![Sequencing electropherograms showing CYP11B1 mutations.](edmcr-2015-150074-g001){#fig1}

Treatment
=========

Hydrocortisone treatment was initiated (15 mg/m^2^ per day) and proband is followed up regularly at our hospital.

Outcome and follow-up
=====================

Four years after presentation the proband remains normotensive. Her growth pattern is normal ([Fig. 2](#fig2){ref-type="fig"}) and the bone age remains advanced (bone age is 7.5 years old at the chronological age of 5 years), despite adequate suppression of adrenal androgens ([Table 3](#tbl3){ref-type="table"}).

![Height for age chart of a girl with 11β-hydroxylase deficiency. Red dots depict actual height; orange dots depict bone age; TH, target height.](edmcr-2015-150074-g002){#fig2}

###### 

Hormone evaluation during treatment (chronological age 5 years old)

  **Laboratory findings**          **Patient values**   **Normal values**
  -------------------------------- -------------------- -------------------
  DHEAS (μg/dl)                    10                   2.8--85.2
  Δ4-androstenedione (ng/ml)       0.72                 0.05--0.45
  17-hydroxyprogesterone (ng/ml)   1.24                 0.2--0.5
  11-deoxycortisol (ng/ml)         46.7                 \<6
  Testosterone (ng/dl)             2                    2--10
  PRA (ng/ml per h)                2.66                 0.5--4.7
  Aldosterone (ng/dl)              14.2                 4--76

Discussion
==========

In the present study, we have reported a Greek girl carrying two novel mutations (p.Ala386Glu and p.Leu471Arg) of the *CYP11B1* gene who shows a typical hormonal 11OHD phenotype with highly elevated steroid hormones and prenatal mild virilization of the external genitalia. Humans have two 11β hydroxylase isoenzymes CYP11B1 (also termed 11β-hydroxylase, P450c11) and CYP11B2 (aldosterone synthase, P450c18) that are responsible for cortisol and aldosterone biosynthesis respectively. CYP11B1 is expressed in high levels in the zona fasciculata and is regulated by ACTH. CYP11B2 is expressed in the zona glomerulosa under primary control of the renin-angiotensin system [@bib6].

Steroid 11β-OHD is the result of *CYP11B1*mutations inherited as an autosomal recessive trait. *CYP11B1*resides on the long arm of chromosome 8, consists of nine exons and shares high sequence homology (95% in coding and 97% in non-coding regions) with *CYP11B2*. More than 90 mutations including missense/nonsense, splicing, small/gross deletions, insertions and complex rearrangements have been reported in the entire encoding region, although they tend to cluster in exons 2, 6, 7 and 8 [@bib2] [@bib3] [@bib7] [@bib8]. Genetic recombination between the two homologs, *CYP11B1* and *CYP11B2*, and crossing over during meiotic reduction do occur. Specifically, an unequal recombination between *CYP11B1* and *CYP11B2* has been found in 11β-OHD CAH affected subjects resulting in variable clinical manifestations [@bib9]. Virilization and hypertension are the main clinical features, the severity of which depends on age. Regarding newborn females, *in utero* androgen excess results in ambiguous genitalia, whereas in the male newborn, diagnosis may go undetected. In infancy and childhood, adrenal androgen overproduction results in peripheral precocious puberty in boys and various degrees of virilization in girls. Without treatment, growth acceleration and advanced bone age results in early epiphyseal maturation and short final stature [@bib10]. Accumulation of DOC and its metabolites causes hypertension in about two-thirds of patients. Potassium depletion develops concomitantly with sodium retention -- although the degree of hypokalemia varies -- renin is suppressed and aldosterone production is low, secondary to low serum potassium and low plasma renin. Hypertension in not usually identified until late childhood or adolescence, although there is a report of an infant 3 months of age with elevated blood pressure [@bib11]. Clinical signs of mineralocorticoid excess and the degree of virilization are not well correlated. Thus, some severely virilized females are normotensive, whereas mildly virilized patients might experience severe hypertension [@bib10]. A mild non-classic form of 11OHD is caused by partial impairment of CYP11B1 function. The female patients are born with normal genitalia and present with signs of androgen excess as children and with signs and symptoms suggestive of polycystic ovary syndrome in adult women. The increasing number of mutations associated with non-classic 11β-OHD illustrate that this disease should be considered as a diagnosis in patients with otherwise unexplained hyperandrogenism.However, unlike classic 11β-OHD, arterial hypertension is not commonly found in the non-classic form [@bib12].

There is no consistent correlation between a specific *CYP11B1* gene mutation and the clinical phenotype of 11β-OHD. In our case, the proband had normal blood pressure and electrolyte profile. In fact, at presentation, plasma renin activity (PRA) was elevated, a finding that could not be attributed to the disorder or her hydration status that was normal. However, at subsequent determinations, while on hydrocortisone, PRA was normal. The mild clinical signs of androgen excess that the patient presented suggest a mild phenotype-associated mutation.

Diagnosis lies on elevated non-11β-hydroxylated products, predominantly 11-deoxycortisol and DOC plus upstream precursors, such as 17α-hydroxyprogesterone and Δ4A. The prevalence of 11β-OHD may be underestimated because biochemical confirmation of clinically suspected CAH is routinely investigated by checking serum 17OHP alone, and thus some patients with 11β-OHD may be misdiagnosed as presenting with a 21a-hydroxylase deficiency. A careful steroid evaluation of serum 17OHP with 11-deoxycortisol, which also allows for detection of cases of apparent combined 21OHD and 11β-OHD, is proposed when clinically indicated [@bib13]. Furthermore, molecular genetic analysis of extracted fetal DNA allows prenatal diagnosis of 11β-OHD. The established protocol of prenatal diagnosis and treatment of 21OHD can be applied to 11β-OHD as well [@bib14].

Steroids form the milestone of the management of CAH. Postnatally, the established treatment of steroid 11β-OHD is similar to that of steroid 21-OHD and consists of glucocorticoid administration to reduce ACTH-driven DOC overproduction resulting in hypertension remission. The optimal goal is to sufficiently restore glucocorticoid production while minimizing adrenal androgen production and cortisol excess. In selected cases, surgical correction of the ambiguous external genitalia in virilized females is mandatory. Oral hydrocortisone is preferred with a typical dose of 10--15 mg/m^2^ per day in divided doses. Long-acting glucocorticoids may be optional at or near the completion of linear growth [@bib15].

In conclusion, we report the first case of 11β-OHD in Greece due to compound heterozygosity for two novel *CYP11B1*mutations associated with mild virilization. Whether the patient will develop hypertension remains to be investigated during long-term follow-up.
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